Getinge AB (0GZV) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Getinge AB SEK 240, price SEK 247, upside -3.0%, quality 64 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Getinge AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range kr 157.35 – kr 388.31 · fair‑value band kr 179.92 – kr 299.87 · the kr 247.35 price screens above the kr 239.89 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments in Sweden and internationally. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments.
Show more
Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments in Sweden and internationally. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, advanced patient monitoring, ICU infrastructure equipment, and drainage solutions. In addition, the company provides surgical perfusion, endoscopic vessel harvesting, intra-aortic balloon counterpulsation, vascular and cardiothoracic surgery equipment, peripheral stenting, OEM solutions, and beating heart surgery equipment; and operating room equipment, anesthesia, advanced patient monitoring, and operating room integration solutions. Further, it offers pre-cleaning, cleaning and disinfection, sterilization, consumables, endoscope reprocessing, and sterile supply management solutions; connected medical devices, and patient flow management; and low temperature sterilization, biocontainment in vaccine production, terminal sterilization, sterile isolation technology, cleaning and sterilization, aseptic transfer, and large-scale cultivation. Additionally, the company provides bioreactor preparation solution, bioprocess development and optimization, labware cleaning and sterilization, biocontainment, and vivarium. It offers its products through a network of sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia and Pacific. Getinge AB (publ) was founded in 1904 and is headquartered in Gothenburg, Sweden.
Stock analysis
Getinge AB (0GZV) currently trades at kr 247.35, while our model-based Fair Value estimate is kr 239.89, so the stock looks roughly fairly valued today (gap 3.1%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 287.02 per share, and 11 of the 24 models we run sit above the kr 247.35 price.
Bear case: the Dividend Discount group reads lowest at kr 38.68, and 13 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: kr 179.92 (bear) to kr 299.87 (bull), the price of kr 247.35 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Getinge AB reported revenue of 27.0B SEK in FY2021 versus 22.5B SEK in FY2017, a compound +4.7%/yr. Reported net income was 3.0B SEK in FY2021, compounding +21.2%/yr from FY2017.
Key figures
Market cap 62.1B SEK (≈ $6.2B) · P/E ratio 0.2 · P/S ratio 0.02 · EPS (TTM) kr 10.50 · Dividend yield 1.9% · Net margin 11.0% · Return on equity 9.0% · Return on assets (EBIT) 5.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 1% below its 52-week high and 40% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −3%, 0GZV screens richer than that median.
Fair Value models
Bear kr 179.92Fair Value kr 239.89Bull kr 299.87
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.52/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−9.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.8%
’17
’18
’19
’20
’21
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
6.6% (2017) → 16.2% (2021)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 348 stocks
Beats the industry median on 7/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score64 · Above median
Fair Value upside−0.4% · Above median
Profitability
Return on equity (TTM)9.0% · Above median
Return on assets5.3% · Above median
Net margin (TTM)7.8% · Above median
Operating margin (TTM)16.1% · Top 25%
Growth and dividend
Revenue growth1.7% · Below median
Dividend yield (TTM)1.9% · Below median
Balance sheet
Debt / equity0.13× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Getinge AB Fair Value". https://www.fairvalue-calculator.com/stock/0GZV
Frequently asked questions
Is Getinge AB (0GZV) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of kr 239.89 versus a price of kr 247.35, about −3% upside (fairly valued).
What is the fair value of 0GZV?
Our model-based fair value for Getinge AB is kr 239.89 (as of Sep 23, 2026), built from audited fundamentals. The current price: kr 247.35.
What is the quality score of 0GZV?
Getinge AB has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Getinge AB (0GZV)?
Our model-based price target is the fair value of kr 239.89 (as of Sep 23, 2026) from 24 valuation models. Cautious scenario kr 179.92, optimistic scenario kr 299.87. It is a calculation from audited fundamentals, not an analyst target.
What is the Getinge AB stock forecast for 2026?
Our models put fair value at kr 239.89, about −3% upside versus a price of kr 247.35 (fairly valued). Cautious scenario kr 179.92, optimistic scenario kr 299.87. The calculation is refreshed regularly with new filings.
What is the revenue of Getinge AB (0GZV)?
Getinge AB reported trailing-twelve-month revenue of about 34.2B SEK (latest available figure, as of Sep 23, 2026).
Does Getinge AB pay a dividend?
Getinge AB currently shows a dividend yield of about 1.92% relative to its recent price (as of Sep 23, 2026).
What is the intrinsic value of Getinge AB (0GZV)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Getinge AB it is kr 239.89 per share (as of Sep 23, 2026), against a price of kr 247.35. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Getinge AB stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 0GZV trades above its calculated fair value: price kr 247.35, fair value kr 239.89, a gap of about −3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0GZV?
No. The price is what the market pays today (kr 247.35); the fair value is what the company's own numbers justify (kr 239.89). For Getinge AB the two are kr 7.46 per share apart. That gap is exactly why we show both numbers side by side.
How much is Getinge AB worth?
The market values Getinge AB at about 62.1B SEK (market capitalisation, as of Sep 23, 2026). Per share that is kr 247.35; our models calculate a fair value of kr 239.89 per share.
What do the bullish and bearish scenarios say about 0GZV?
Our models span a range for Getinge AB: cautious scenario kr 179.92, base kr 239.89, optimistic kr 299.87 per share (as of Sep 23, 2026, price kr 247.35). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0GZV?
Getinge AB trades at a price-to-earnings ratio of 0.2 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 239.89 is built from several models across several years.
How solid is the balance sheet of Getinge AB (0GZV)?
Balance-sheet figures for Getinge AB (as of Sep 23, 2026): return on equity 9.0%, debt of 0.13 per unit of equity. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is 0GZV from its 52-week high?
Getinge AB trades at kr 247.35, about 1% below its 52-week high of kr 250.40 and 40% above the low of kr 176.68 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of kr 239.89 is for.
Which stocks are comparable to Getinge AB?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Getinge AB stock attractive at the current price?
The data as of Sep 23, 2026: price kr 247.35, calculated fair value kr 239.89 (−3%), Quality Score 64/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0GZV calculated?
We run Getinge AB through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 239.89, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Getinge AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Getinge AB (0GZV)?
The closing price on Oct 2, 2026 was kr 247.35. Our model-based fair value is kr 239.89, about −3% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Getinge AB right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Getinge AB
How large is the market capitalisation of Getinge AB (0GZV)?
The market capitalisation of Getinge AB is 62.1B SEK (≈ $6.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Getinge AB (0GZV)?
The price-to-sales ratio of Getinge AB is 0.02 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Getinge AB (0GZV)?
Earnings per share at Getinge AB are kr 10.50 (price ÷ EPS = P/E 0.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Getinge AB (0GZV)?
The dividend yield of Getinge AB is 1.9% (payout 45.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Getinge AB (0GZV)?
The net margin of Getinge AB is 11.0% (fiscal year 2021). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Getinge AB (0GZV)?
The return on equity (ROE) of Getinge AB is 9.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Getinge AB (0GZV)?
On an EBIT basis the return on assets of Getinge AB is 5.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Getinge AB (0GZV)?
The operating margin of Getinge AB is 16.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Getinge AB (0GZV)?
Revenue at Getinge AB is growing +1.7% versus a year earlier (3y avg +3.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Getinge AB (0GZV)?
Earnings per share at Getinge AB are growing +60.5% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Getinge AB in the live analysis
One click puts Getinge AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
